Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. Co.'s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which Co. refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target main nodes in the RAS pathway or associated pathways, which Co. refers to as RAS Companion Inhibitors. Co.'s RAS Companion Inhibitors (example, SHP2, mTORC1 and SOS1 inhibitors) are designed primarily for combination treatment strategies involving one or more therapeutic agents, which may include its RAS(ON) Inhibitors. The RVMD YTD return is shown above.
The YTD Return on the RVMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether RVMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RVMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|